Based on our findings, further in vivo and in vitro studies are planned to validate the potential of these identified antigens as targets for immunotherapy in CRC liver metastases (e.g., EphB4 CAR-T trial for EphB4-positive CRCLM). The gene discussed is EPHB4; the disease is colorectal carcinoma.